Literature DB >> 10384110

Bioactive IL-18 expression is up-regulated in Crohn's disease.

G Monteleone1, F Trapasso, T Parrello, L Biancone, A Stella, R Iuliano, F Luzza, A Fusco, F Pallone.   

Abstract

An imbalance of immunoregulatory factors is believed to contribute to uncontrolled mucosal Th1 cell activation in Crohn's disease (CD). IL-18, a macrophage-like cell-derived cytokine, is involved in Th1 clone development, and IFN-gamma production. Therefore, IL-18 expression was investigated in CD. Whole mucosal intestinal tissue and lamina propria mononuclear cells (LPMC) of 12 CD and 9 ulcerative colitis (UC) patients and 15 non-inflammatory bowel disease (IBD) controls were tested for IL-18 by semiquantitative RT-PCR and Western blot analysis. Transcripts for IL-18 were found in all samples tested. However, increased IL-18 mRNA accumulation was detected in both mucosal and LPMC samples from CD in comparison to UC and controls. In CD, transcripts for IL-18 were more abundant in the mucosal samples taken from involved areas. An 18-kDa band consistent with mature IL-18 was predominantly found in CD mucosal samples. In mucosal samples from non-IBD controls, IL-18 was present as a 24-kDa polypeptide. Consistently, active IL-1beta-converting enzyme (ICE) subunit (p20) was expressed in samples from either CD or UC, whereas, in colonic mucosa from non-IBD controls, ICE was synthesized as precursor (p45) only. To confirm that IL-18 produced in CD tissue was functionally active, CD LPMC were treated with a specific IL-18 antisense oligonucleotide. In these cultures, IL-18 down-regulation was accompanied by a decrease in IFN-gamma expression. In aggregate, our data indicate that IL-18 up-regulation is a feature of CD and suggest that IL-18 may contribute to the local immunoinflammatory response in CD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384110

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  113 in total

Review 1.  Interleukin-18, rheumatoid arthritis, and tissue destruction.

Authors:  J M Dayer
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Cytokines in experimental colitis.

Authors:  P Garside
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 3.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 4.  Ups and downs of mucosal cellular immunity against protozoan parasites.

Authors:  L H Kasper; D Buzoni-Gatel
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 5.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis.

Authors:  T Yamano; T Higashi; K Nouso; H Nakatsukasa; K Kariyama; E Yumoto; Y Kobayashi; K Yamamoto; H Iwagaki; T Yagi; T Tanimoto; M Kurimoto; N Tanaka; T Tsuji
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

7.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

8.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

Authors:  A Sturm; A Z A Leite; S Danese; K A Krivacic; G A West; S Mohr; J W Jacobberger; C Fiocchi
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  Maternal obesity induces gut inflammation and impairs gut epithelial barrier function in nonobese diabetic mice.

Authors:  Yansong Xue; Hui Wang; Min Du; Mei-Jun Zhu
Journal:  J Nutr Biochem       Date:  2014-04-01       Impact factor: 6.048

10.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.